Defibrotide Compassionate Use for Patients With Life Threatening Veno-Occlusive Disease of the Liver

• Status: No longer available
• Trial end date: 2009-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Severe veno-occlusive disease (VOD) of the liver is a life threatening complication of blood and marrow transplantation. Treatment with currently available (Food and Drug Administration [FDA] approved) agents fails in most cases. Recently conducted clinical studies indicate that patients benefit from defibrotide, a non-FDA approved agent. This protocol has been developed not with a research intent, but rather to ensure that defibrotide is used by the blood and marrow transplant programs at Children's Healthcare of Atlanta and at Emory University in a safe, effective and ethical manner.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Emory University
• Treatments: Defibrotide

Criteria

Inclusion Criteria:

• Veno-occlusive disease of the liver